How to Prepare Performance Verification Documentation for Overseas Registration of Home-Use Medical Devices?

To prepare performance verification documentation for overseas registration of home-use medical devices, you must first determine whether the target country regulates the product as a medical device and confirm its risk classification and registration pathway. Most home-use products fall into Class II or IIa, and typically you will need to submit performance verification reports, risk management documentation, electrical safety and EMC reports, software validation evidence (if applicable), and clinical evaluation or usability testing evidence. Do not simply reuse NMPA or CE files; instead, assess local differences in standards, testing laboratory qualifications, and language requirements. Common pitfalls include failure to retest according to local standards, lack of a local agent or authorized representative, non-compliant labeling and instructions, inconsistencies between performance claims and verification results, and incomplete biocompatibility testing. You should define the registration pathway and target markets at the project planning stage, plan testing, build a reusable master technical file, and engage an experienced local agent for submission, deficiency responses, and post-market maintenance. GHWP member countries and Southeast Asian, Middle Eastern, and Latin American markets generally accept technical documentation based on ISO 13485 and IEC standards, but localization and gap analysis are required.

Intended Use and Core Considerations

Home-use medical devices include blood pressure monitors, blood glucose meters, thermometers, oxygen concentrators, ventilators, physiotherapy devices, and home-use diagnostic reagents. When preparing for overseas registration, first verify whether the target country defines the product as a medical device and whether marketing authorization is required. Regulatory scope, risk classification, and registration requirements vary considerably by country. The U.S. FDA may manage some home-use devices as OTC medical devices; the EU MDR emphasizes intended purpose and patient safety; Southeast Asian, Middle Eastern, and Latin American countries each have their own regulatory systems.

Performance verification documentation is intended to demonstrate that the product meets its claimed performance indicators under intended use conditions and is safe and reliable for users, especially non-professionals. Users of home-use products may have no medical background, and factors such as age, operating habits, and environmental conditions vary. Therefore, performance verification must cover not only standard testing but also usability, environmental adaptability, and the impact of labeling and instructions.

A common question is whether existing domestic registration certificates or CE certificates can be used directly for overseas registration. The answer is that some materials can be reused, but simple translation and submission are not sufficient. A gap analysis is required to confirm whether the standards, test methods, limits, and requirements adopted by the target country align with existing documentation.

This article is intended for companies already registered in China or preparing to export home-use medical devices, to help clarify the specific content, organization, and common risks of performance verification documentation. It provides an actionable decision logic and preparation checklist for regulatory teams or CROs.

Registration Determination Logic

Follow a top-down approach:

• Determine whether the product falls within the target country’s medical device regulatory scope. Some home-use products may be classified as health consumer goods or non-medical devices in certain countries; however, adding therapeutic claims can bring them under medical device regulation.
• Confirm the risk classification and registration pathway. Home-use products typically fall into Class II or IIa, but the specific classification rules of the target country apply. The U.S. FDA uses its product classification database to determine whether a 510(k) or De Novo request is needed; the EU MDR requires a notified body; and most Southeast Asian countries use a 'reference regulatory agency' or 'applicable agency review' approach, such as Singapore’s HSA, Malaysia’s MDA, and Thailand’s TFDA.
• Assess the reusability of existing documentation. Inventory existing NMPA registration documents, CE technical files, FDA 510(k) submissions, or ISO 13485 system files, and review relevant standard differences and language requirements.
• Confirm local agent and authorized representative requirements. Most countries mandate that overseas manufacturers designate a local agent or authorized representative for registration, communication, and post-market surveillance. Without a local agent, applications are typically not accepted.
• Develop a performance verification strategy. Performance verification documentation is not a one-time folder delivery but an evidence chain built around product standards, risk management, clinical evaluation, and labeling. Define the product’s intended use, key performance indicators, acceptable limits, and test methods early, and generate verification reports accordingly.

For GHWP member countries and multi-country registration, prioritize building a Master Technical File and a regional difference table so that each report can be accepted by multiple countries, reducing redundant testing and recompilation.

Documentation and Evidence

Performance verification documentation typically includes the following modules:

• Product technical requirements or performance specifications
• Performance test reports
• Risk management reports
• Electrical safety reports
• Electromagnetic compatibility (EMC) reports
• Environmental testing reports
• Biocompatibility reports (if the product contacts the body)
• Software validation reports (if applicable)
• Clinical evaluation or usability testing reports
• Labels and instructions for use

Product technical requirements must specify the model, structure composition, working principle, intended use, operating environment, and quantified performance and safety indicators. Performance test reports must be based on standard methods recognized by the target country or validated equivalent methods, and state the sample quantity, test conditions, actual results, and deviations.

Risk management reports should be established according to ISO 14971, including risk analysis, risk evaluation, risk control measures, and residual risk evaluation. For home-use devices, special attention should be given to misuse, electrical environment, electromagnetic interference, cleaning, and disinfection scenarios.

For electrical safety and EMC testing, the IEC 60601 series standards are preferred, but additional testing may be required if the target country has national standards or deviations. For example, Brazil may require INMETRO certification, Saudi Arabia requires SASO certification, and Japan requires a PMDA application.

Biocompatibility testing should follow the ISO 10993 series and confirm contact duration, contact site, and material composition. Sensors, housings, and battery compartments of home-use products may come into contact with users; test items should be determined based on risk assessment.

Software validation documentation must align with IEC 62304 or recognized software lifecycle requirements, including requirements specifications, software architecture, verification, and validation records. Home-use products often include apps or wireless connectivity; software change control is also a review focus.

For clinical evaluation or usability testing, some regulatory authorities require clinical evidence or human factors validation to demonstrate that target users can operate the device safely and effectively. Usability tests should simulate real-world use, including readability of instructions and clarity of warning symbols.

Labels and instructions for use are supplementary evidence because labeling directly affects performance claims and user operation. They must be localized according to the target country’s language, symbols, units of measurement, and warning statements.

The complete documentation package should also include quality management system inspection documents, such as an ISO 13485 certificate or MDSAP certificate, as well as supplier information and batch records. These documents are not performance verification per se, but they are reviewed during registration.

Common Pitfalls

Common pitfalls include:

• Directly translating NMPA or CE reports without verifying that standard versions are accepted in the target country.
• Ignoring the necessity of local agents or authorized representatives, leading to application rejection or indefinite suspension.
• Performance claims not supported by corresponding verification reports.
• Submitting only type-test reports while lacking risk management, usability, software validation, and other supporting documents.
• Labels and instructions not localized, with non-compliant units, symbols, or language.
• Testing laboratories that do not hold recognized qualifications in the target country.
• Overlooking special use conditions of home-use devices, such as operation by the elderly, use with wet hands, or accidental access by children.
• Missing post-market performance and safety data collection mechanisms to handle post-approval inspections.

Preparation Checklist for Companies

Recommended preparation checklist:

• Build a regulatory database for target countries, recording classification rules, registration pathways, applicable standards, and language requirements.
• Develop a project timeline that includes performance testing, documentation compilation, local agent contracting, submission, and deficiency response.
• Define the structure of a master technical file in a modular format so it can be reused across countries.
• Contact recognized laboratories in target countries to confirm standard versions, sample quantities, and testing lead times.
• Complete the risk management report and update descriptions of intended use and operating environment.
• Collect material certifications, ISO certificates, and test reports from all suppliers.
• Prepare software validation documentation (if applicable), including a requirements traceability matrix and cybersecurity statements.
• Draft or update labels and instructions for use, and have them reviewed by native speakers or the local agent.
• Sign a local agent agreement that clearly assigns responsibilities for registration certificate ownership, changes, and renewals.
• Establish a post-market surveillance process to collect complaints, adverse events, and performance data.

AIMEILI Perspective

A common misjudgment is assuming that a CE report is sufficient. In reality, differences in standards, classifications, and language requirements across countries can cause significant rework. Even a high-quality CE report requires a gap analysis and may need supplementary local tests or documents.

At the early project stage, conduct a market access assessment to determine priorities and feasibility. Do not rush into a full set of tests; instead, list target countries, analyze standards and regulatory differences, and then decide on the testing plan. This approach saves cost and time.

Reusable documentation includes product technical requirements, risk management framework, design verification data, ISO 13485 system documents, and electrical safety test reports (if standards align). Documentation that must be localized includes labels and instructions, registration application forms, local agent documents, local-language risk management summaries, and certain locally required tests.

The value of a local agent extends far beyond submission. The agent receives regulatory notices, supports post-market inspections, handles adverse event reporting, and assists with changes and renewals. Poor agent service may result in loss of control over the registration certificate or even market supply disruption.

For multi-country registrations, establish a 'master technical file + country difference table' mechanism. Each test report should clearly state the test method, standard version, and test conditions so that assessors in each country can quickly understand it. In addition, plan change management processes in advance to avoid recompiling the entire documentation set when a change occurs in one country.

AIMEILI recommends confirming expected deficiency responses with the local agent before registration, assigning a dedicated regulatory coordinator, and using project management tools to track testing, translation, notarization, and apostille steps. Registration is not a one-time project but part of ongoing post-market maintenance.

Frequently Asked Follow-up Questions

Q1: Do home-use medical devices require clinical evaluation for overseas registration? Not necessarily. The scope of clinical evaluation depends on the product risk class, availability of equivalent products, and the target country’s regulations. Many home-use devices can complete clinical evaluation through literature review or equivalent device comparison. If the product claims a novel function or is intended for a specific population, the regulator may require a clinical investigation. Companies should first develop a clinical evaluation plan and then determine whether clinical trials are needed based on target country requirements.

Q2: Must performance verification reports be issued by laboratories in the target country? Not all countries require local laboratory testing. Common practice is to accept reports from ISO 17025-accredited laboratories or laboratories with international recognition agreements. However, some countries, such as Brazil, Russia, and India, may require local testing or local laboratory participation. We recommend confirming report acceptance with the local agent before project initiation to avoid rejection due to laboratory qualification issues.

Q3: Can existing domestic registration documentation be used directly for overseas registration? No, but it can serve as a basis. Domestic product technical requirements and test reports must be compared with the target country’s standards. For example, Chinese GB standards may reference IEC or ISO, but there may be differences in edition versions and limits. Companies should create a gap comparison table to identify additional tests needed. For quality management system certificates, ISO 13485 certificates can generally be used directly for overseas registration, but NMPA system inspection records cannot replace ISO system certification.

Further Reading

Recommended articles include:

• How to Determine Product Classification for Overseas Registration of Software Medical Devices
• How to Select a Local Agent for Overseas Registration of Software Medical Devices
• Why Does the Overseas Registration Cycle for Software Medical Devices Keep Getting Extended?
• When Should Registration Changes Be Filed for Software Medical Devices?
• Why Does the Registration Cycle for POCT Products Keep Getting Extended?
• What Are Common Reasons for Deficiency Responses in POCT Product Registration?

Source and Applicability

Content Author: AIMEILI Regulatory Editorial Department

Professional Reviewer: AIMEILI Medical Device International Registration Project Team

This article is compiled from AIMEILI's registration practice question bank, international medical device registration knowledge base, and public regulatory information. For specific projects, the latest requirements of the target country's regulatory authority and the product's documentation basis should prevail.

Source Principles: Priority is given to official regulatory agencies, international organizations, standards organizations, and publicly available regulatory documents; industry media and project experience are used as supplementary reference.

Applicability: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace formal requirements of target country regulatory authorities, testing conclusions, or legal advice.

Published: July 31, 2026 | Updated: July 31, 2026